title: Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
abstract: We retrospectively reviewed time to response and incidence of delayed responses in 13 patients with lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia (LPL/WM) treated with fludarabine with or without cyclophosphamide. During follow-up post-treatment, seven delayed responses (54%) were observed, improving the initial overall response rate of 61% to a final response rate of 77%.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Del Giudice
authors.forename: Estella
authors.initials: E
authors.lastname: Matutes
authors.forename: Nnenna
authors.initials: N
authors.lastname: Osuji
authors.forename: Nilima
authors.initials: N
authors.lastname: Parry-Jones
authors.forename: John
authors.initials: J
authors.lastname: Swansbury
authors.forename: Daniel
authors.initials: D
authors.lastname: Catovsky
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine